Ashley Courchesne
Family · New Braunfels, TXNPI 1922528645
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,406 and has fallen 66.0% since, to $478 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$539
- Revance Therapeutics, Inc.$533
- Novo Nordisk$474
- Merz North America, Inc.$355
- Galderma Laboratories, L.p.$295
- Astellas Pharma US Inc$264
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,14898%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $539 |
| Revance Therapeutics, Inc. | 20 | $533 |
| Novo Nordisk | 25 | $474 |
| Merz North America, Inc. | 6 | $355 |
| Galderma Laboratories, L.p. | 8 | $295 |
| Astellas Pharma US Inc | 10 | $264 |
| Lilly USA, LLC | 23 | $224 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $182 |
| Abbott | 5 | $160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $125 |
| Tarsus Pharmaceuticals, Inc. | 1 | $117 |
| AstraZeneca | 7 | $110 |
| Medtronic | 3 | $108 |
| Amarin Pharma, Inc. | 7 | $98 |
| Amgen | 5 | $97 |
| GSK | 5 | $81 |
| Johnson & Johnson | 4 | $70 |
| Bayer | 3 | $59 |
| Mannkind Corporation | 3 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Pfizer | 2 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $36 |
| Novartis | 2 | $30 |
| SK Life Science, Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Itamar Medical Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,233 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 56 | $3,488 |
Paid to pharmacies, not to this prescriber.
Other family in New Braunfels
- Jeremy SchmidtNew Braunfels$132K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.